Key Highlights
- Veea (NASDAQ:VEEA) rose 47.29% to USD 5.70 in the October 9, 2026 session on volume of 694,488 shares, about 0.10 times its three-month average of 6.665M, which is simple arithmetic on two published numbers.
- Novavax (NASDAQ:NVAX) gained 15.80% to USD 12.75, close to its 52-week high of USD 13.39, and no company-specific catalyst was identified for the session, so the move reflects published market data.
- C4 Therapeutics (NASDAQ:CCCC) rose 10.88% to USD 3.16 on 2.828M shares. Recursion Pharmaceuticals (NASDAQ:RXRX) rose 10.38% to USD 4.36 on 30.79M shares, about 1.5 times its three-month average, simple arithmetic.
- All four are names with high short interest positions, and they gained while the S&P 500 closed at 7,811.5, just below its record, with the CPI report due October 14 at 8:30 a.m. ET.
Veea (NASDAQ:VEEA): A Large Gain on Thin Volume
Veea (NASDAQ:VEEA) develops an edge computing and artificial intelligence platform, including the VeeaHub and VeeaONE products, and became public through a SPAC merger. Shares rose 47.29%, or USD 1.83, to USD 5.70 in the October 9, 2026 session, against a 52-week range of USD 1.34 to USD 18.68 and a market capitalization of USD 240.769M. Volume was 694,488 shares against a three-month average of 6.665M, about 0.10 times, simple arithmetic on two published numbers. A large gain on light volume means few shares changed hands, which can make a price easier to move in either direction. Earlier context exists: on October 1, 2026 TROLLEE Holdings announced a phased VeeaONE rollout across 1,000 unattended stores, starting with up to 50 locations, and shares rose 43.3% that day. That deal is earlier context only, and no company-specific catalyst was identified for the October 9 session. Veea (NASDAQ:VEEA) also has a high short interest position, so buying by short sellers closing positions can add to a rise, though the published data cannot confirm that cause.
Novavax (NASDAQ:NVAX): Near the Top of Its Range
Novavax (NASDAQ:NVAX) makes protein-based vaccines and has a partnership with Sanofi. It rose 15.80%, or USD 1.74, to USD 12.75 in the October 9, 2026 session, within reach of its 52-week high of USD 13.39 and well above the low of USD 6.20, for a market capitalization of USD 1.816B. Volume of 6.199M shares was about 1.2 times the three-month average of 5.159M, simple arithmetic on two published numbers. Earlier in the week, on October 5, shares rose about 10.5% to about USD 11.56, and no catalyst was identified then either. None was identified for the October 9 move, which reflects published market data. Revenue in the quarter reported on August 6 was USD 56.7M, down 76.2% from a year earlier, with an adjusted loss of USD 0.32 per share against USD 0.38 expected. For a name with a high short interest position, a rise this size can force short sellers to buy back shares, and that buying adds to the gain. This mechanism is general and has not been confirmed for Novavax (NASDAQ:NVAX) specifically.
C4 Therapeutics (NASDAQ:CCCC): Degrader Medicines and Cash Runway
C4 Therapeutics (NASDAQ:CCCC) develops targeted protein degradation medicines for cancer, which direct the cell's own disposal machinery to remove disease-causing proteins instead of only blocking them. Shares rose 10.88%, or USD 0.31, to USD 3.16 in the October 9, 2026 session, inside a 52-week range of USD 1.69 to USD 5.17 and with a market capitalization of USD 350.622M. Volume of 2.828M shares was about 1.2 times the three-month average of 2.383M, simple arithmetic on two published numbers, so participation was only modestly elevated. No company-specific catalyst was identified for the session, and the move reflects published market data. Clinical-stage companies usually have no meaningful product revenue, so the share price rests on trial progress, partnership payments and cash runway, the length of time cash can fund operations. When cash runs short, companies sell new shares, which dilutes existing holders. The Fed policy rate of 3.75% to 4.00% after the September hike and a 10-year Treasury yield near 5.25% raise the cost of outside funding for C4 Therapeutics (NASDAQ:CCCC) and similar developers.
Recursion Pharmaceuticals (NASDAQ:RXRX): The Largest Volume Ratio
Recursion Pharmaceuticals (NASDAQ:RXRX) uses artificial intelligence and automation to discover drugs, and it combined with Exscientia in late 2024. Shares rose 10.38%, or USD 0.41, to USD 4.36 in the October 9, 2026 session, within a 52-week range of USD 2.77 to USD 7.18 and with a market capitalization of USD 2.118B, the largest of the four. Volume reached 30.79M shares, about 1.5 times the three-month average of 20.563M, simple arithmetic on two published numbers and the highest volume ratio of the four. No company-specific catalyst was identified, and the move reflects published market data. Drug developers that pair artificial intelligence with biology tend to attract interest when sentiment toward artificial intelligence improves, yet semiconductors fell more than 4% last week, so sentiment has been mixed. Drug discovery is slow and costly, and most candidates fail in trials, so shares depend on pipeline readouts and funding. A sharp rise on above-average volume is also the pattern seen when short sellers cover, but Recursion Pharmaceuticals (NASDAQ:RXRX) cannot be tied to that cause from published data.
Where Things Stand
The four rose because buyers outnumbered sellers in the October 9, 2026 session, but no company-specific catalyst was identified for any of them, so the moves reflect published market data. Veea stands out for a 47.29% gain on volume far below its average, while Novavax, C4 Therapeutics and Recursion Pharmaceuticals rose between 10.38% and 15.80% on volume at or above their averages. High short interest positions can amplify gains when shorts buy back shares, but that cannot be confirmed here. The next markers are bank earnings from October 13 and the CPI report on October 14 at 8:30 a.m. ET. None of this is a forecast.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...